Cargando…
PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy
The mineralocorticoid receptor (MR) antagonists PF-03882845 and eplerenone were evaluated for renal protection against aldosterone-mediated renal disease in uninephrectomized Sprague-Dawley (SD) rats maintained on a high salt diet and receiving aldosterone by osmotic mini-pump for 27 days. Serum K(+...
Autores principales: | Orena, Stephen, Maurer, Tristan S., She, Li, Eudy, Rena, Bernardo, Vincent, Dash, Darla, Loria, Paula, Banker, Mary E., Tugnait, Meera, Okerberg, Carlin V., Qian, Jessie, Boustany-Kari, Carine M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3796291/ https://www.ncbi.nlm.nih.gov/pubmed/24133446 http://dx.doi.org/10.3389/fphar.2013.00115 |
Ejemplares similares
-
The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism
por: Eudy, Rena J, et al.
Publicado: (2011) -
Management of hyperkalemia during treatment with mineralocorticoid receptor blockers: findings from esaxerenone
por: Rakugi, Hiromi, et al.
Publicado: (2020) -
Determinants of Hyperkalemia Progression Among Patients with Mild Hyperkalemia
por: Israni, Rubeen, et al.
Publicado: (2021) -
Combination Therapy Using Sodium Zirconium Cyclosilicate and a Mineralocorticoid Receptor Antagonist in Patients with Heart Failure and Hyperkalemia
por: Imamura, Teruhiko, et al.
Publicado: (2021) -
Renal mineralocorticoid receptor expression is reduced in lipoatrophy
por: Toffoli, Barbara, et al.
Publicado: (2019)